Nephros, Inc. cash flow to debt ratio of 154.75% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Nephros, Inc.'s free cash flow has increased -400.73% from $-547.00K last year to $1.65M, signaling increasing performance

Nephros, Inc.'s debt to equity ratio is 0.07, which means that the company's assets are healthy financed, signaling financial stability.

Nephros, Inc.'s debt has decreased relative to shareholder equity from 0.16 last year to 0.07 today, signaling strengthened financials

Nephros, Inc. has a net cash position, so leverage is healthy.

Nephros, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Nephros, Inc.'s profit margin has increased (1.50K%) in the last year from 0.52% to 8.38%, signaling increasing performance

Nephros, Inc.'s short-term assets of $11.22M exceed its short-term liabilities of $2.77M

Nephros, Inc.'s return on assets of 11.01% is higher than the 5.00% threshold, indicating efficient asset utilization

Nephros, Inc.'s return on equity of 16.20%, is higher than 15.00%, indicating good performance

Nephros, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Nephros, Inc. had positive net income in only 2 out of 5 years, indicating unstable earnings

Nephros, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Nephros, Inc. has a free cash flow yield of 3.46%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Nephros, Inc.'s yearly earnings has increased 1.51K% since last year from $74.00K to $1.19M, signaling increasing performance

Nephros, Inc.'s yearly revenue has increased 32.67% since last year from $14.16M to $18.79M, signaling increasing performance

ROIC 12.67% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Nephros, Inc.'s 3-year revenue CAGR of 23.50% is positive, indicating growing revenue over the past 3 years

Nephros, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Nephros, Inc. had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

Nephros, Inc. has insufficient data to evaluate this check.

Nephros, Inc. has an earnings yield of 3.65%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Nephros, Inc. is overvalued relative to its fair value price of 1.26 based on EBITDA multiple model

Nephros, Inc. has an EV/EBITDA ratio of 32.08x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Nephros, Inc. is overvalued relative to its fair value price of -3.71 based on Earnings Fair Value model

Nephros, Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Nephros, Inc. has a price-to-book ratio of 3.97x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Nephros, Inc. has a price-to-sales ratio of 2.29x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue